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Abstract Drugs targeting inhibition of kinases for the
treatment of inflammation and autoimmune disorders have
become a major focus in the pharmaceutical and biotech
industry. Multiple kinases from different pathways have
been the targets of interest in this endeavor. This review
describes some of the recent developments in the search for
inhibitors of IKK2, Syk, Lck, and JAK3 kinases. It is
anticipated that some of these compounds or newer
inhibitors of these kinases will be approved for the
treatment of rheumatoid arthritis, psoriasis, organ trans-
plantation, and other autoimmune diseases.
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Introduction
Discovery of novel drugs targeting kinases, an important
class of intracellular enzymes that play a critical role in
signal transduction pathways controlling a variety of
cellular functions, has become the focus of a large number
of drug discovery programs in the pharmaceutical and
biotech industry. The role of a kinase in signal transduction
is to catalyze the transfer of the terminal phosphate group of
ATP to an appropriate substrate leading to the activation of
the substrate for its role in the next step of the signaling
cascade. The substrate is often another kinase or a
transcription factor. A large majority of kinase inhibitors
are designed to inhibit the enzyme by binding at or near the
ATP-binding site. Therefore, an inhibitor of one kinase is
often found to inhibit other structurally related or unrelated
kinases. This inherent promiscuity of kinase inhibitors calls
for extensive profiling of the inhibitors either for driving
structure-activity relationship (SAR) during lead optimiza-
tion or for opportunistic discoveries [1, 2].
Currently eight small molecule kinase inhibitor drugs
and a handful of protein/antibody therapeutics targeting
kinases have been approved for human use. A large number
of kinase inhibitor discovery programs have been focused
on drugs for the treatment of inflammation and autoimmune
disorders; however, the approved drugs to date have been
useful for the treatment of a variety of cancers in humans.
One of the reasons cited for this lack of success to date for
kinase inhibitor drugs for the treatment of patients with
inflammation and autoimmune disorders has been the high
hurdle for safety required for the chronic treatment of
patients whose life expectancy is usually significantly
longer than that of cancer patients.
A large number of kinases from different signal
transduction pathways have been the targets of interest for
the treatment of inflammation and autoimmune disorders.
One class of such kinases have been the mitogen-activated
protein kinases (MAP kinases), which has been summa-
rized in a recent review [3], and hence will not be covered
in this chapter. This review will cover the recent publica-
tions, primarily from 2006–2007, describing inhibitors of
IKK2 (IκB kinase 2), Syk (spleen tyrosine kinase), Lck
(lymphocyte-specific kinase), and JAK3 (Janus kinase 3).
Inhibitors of kinases such as BTK and Fyn are not covered
in this review. Some of the publications cited in this review
refer to the inhibitors reported earlier for that kinase. A
large number of patents on kinase inhibitors describe,
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biological profile of compounds. This chapter will not
cover such disclosures. Additionally, a majority of kinase
inhibitors disclosed as having inhibitory activity for one
kinase are found to be potent inhibitors of other kinases.
This review will focus on the kinase inhibitors that are
profiled for a particular kinase with potential application in
inflammation. The inhibitors described for certain kinases,
such as Src family kinases, that inhibit other kinases
relevant to inflammation, but are not profiled for anti-
inflammatory activity, are not included in this review.
IKK2 inhibitors
Nuclear factor (NF)-κB is an important transcription factor
that regulates multiple cell functions. This transcription
factor exists in the cytoplasm in an inactive form because of
its binding to the inhibitory protein, IκB. Upon activation
of the cell following the binding of cytokines and growth
factors or by UV or stress, a signal transduction cascade
unravels that leads to the activation of the serine-threonine
kinases, IKK1 and IKK2. IKK2 phosphorylates the Ser32
and Ser36 residues of IκB bound to NF-κB. The phos-
phorylated complex is ubiquitinated by E3RS ligase and
degraded by proteasome to generate the active NF-κB. The
transcription factor then translocates to the nucleus and
induces the transcription of proinflammatory cytokines and
matrix metalloproteases [4]. Inhibition of IKK2 has been
pursued as a potential therapy to treat disorders related to
inflammation and autoimmunity. Based on the critical role
of NF-κB in the immune system and on the data from
knockout mice, it has been postulated that chronic
inhibition of this transcription factor could lead to oppor-
tunistic infections and hepatic toxicity. However, studies in
transgenic mice and of some of the inhibitors in animals
have indicated that inhibition of NF-κB function is unlikely
to cause systemic infection and apoptosis of hepatic tissue
in animals [5].
The IKK2 inhibitors discussed herein are shown in
Fig. 1. BMS-345541 is reported to be a selective and ATP-
noncompetitive inhibitor of IKK2 with IC50=300 nM [6].
The compound was not a potent inhibitor of IKK1 (IC50=
4 μM). In lipopolysaccharide (LPS)-stimulated THP-1
cells, the expression of proinflammatory cytokines such as
interleukin (IL)-1β, IL-6, and tumor necrosis factor alpha
(TNF-α) was inhibited with IC50=1−5 μM. At a dose of
30 mg/kg administered once daily, BMS-345541 maximally
reduced disease severity in a murine model of dextran
sulfate sodium-induced colitis [7]. The compound dosed at
100 mg/kg (po, qd) in this model showed a similar benefit.
Structural modification of BMS-345541 has resulted in
compounds 1–3, which are significantly more potent
inhibitors of IKK2 with IC50=10−60 nM [8]. In LPS-
stimulated THP-1 cells, compound 1 inhibited TNF-α
production with IC50=0.34 μM, while BMS-345541 was
less potent in this test with IC50=4μM. Oral administration
of compound 1 to mice inhibited the LPS-induced TNF-α
levels in the serum with ED50=10 mg/kg. A structurally
related, imidazo-thieno-pyrazine derivative, 4, has been
reported to inhibit IKK2 with IC50=13 nM and IKK1 with
IC50=390 nM [9]. A 10 mg/kg oral administration of 4 to
mice, 1 h prior to LPS challenge, inhibited TNF-α levels by
50%. However, administration of 4, 4 h prior to LPS
challenge, did not inhibit TNF-α levels, indicating that the
compound has a short half-life.
A series of 2-anilino-4-arylpyrimidines such as com-
pound 5 have been reported to be potent IKK2 inhibitors
with IC50=11 nM for compound 5 [10]. The authors have
not disclosed cellular and in vivo activity profiles of the
compounds and have attempted to explain the SAR using a
homology model of IKK2 and using quantitative structure-
activity relationship (QSAR) models.
In a series of publications, Murata and coworkers have
disclosed optimization of substituted pyridines to identify
compound 6 with IKK2 IC50=8.5 nM [11–13]. Compound
6 was a poor inhibitor of IKK1 with IC50=250 nM.
Compound 6 inhibited LPS-induced TNF-α production in
human PBMCs (peripheral blood mononuclear cells) with
IC50=50 nM. Oral administration of 0.3–3 mg/kg of
compound 6 inhibited the arachidonic acid-induced ear
edema in mice in a dose-dependent manner. The anti-
inflammatory activity of 6 at 1 mg/kg oral dose in this
model was superior to that of dexamethasone at 0.3 mg/kg
oral dose. The oral bioavailability of 6 in rats was 60% with
low clearance (CL=0.33 l/h per kg). Compound 7 has been
reported to be a potent, ATP-competitive, and moderately
selective inhibitor of IKK2 with Ki=2 nM [14]. The
compound inhibited the cytokines and other inflammatory
mediators in a variety of cells upon induction (IC50=47nM
for LPS-induced TNF-α production in PBMCs). Com-
pound 7 had good bioavailability in rats and mice and
showed beneficial effects in animal models of allergy, lung
inflammation, edema, and delayed-type hypersensitivity
(DTH).
Structural modification of SC-415, a known weak but
selective IKK2 inhibitor [15], has yielded compound 8 and
analogs with modest IKK2 inhibitory potency [16].
Compound 8, with IC50=333 nM for inhibition of IKK2,
inhibited IL-8 production in IL-1β-stimulated synovial
fibroblasts derived from rheumatoid arthritis patients with
IC50=832 nM.
A structurally related compound TPCA-1 has been
reported to be an ATP-competitive and selective inhibitor
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cytokines such as TNF-α, IL-6, and IL-8 induced by LPS
in human PBMCs was inhibited by TPCA-1 with IC50=
170-320 nM. A 20 mg/kg oral dose of TPCA-1 adminis-
tered twice daily to mice significantly reduced the clinical
score and disease severity in a collagen-induced arthritis
(CIA) model. Compound 9, an isomer of TPCA-1, has been
reported to be a potent inhibitor of IKK2 with IC50=63nM
and 100-fold selective over IKK1 [18]. In PBMCs, the
LPS-induced TNF-α production was inhibited by 9 with
IC50=400 nM. The compound showed low in vitro
metabolic clearance in rat hepatocytes, low in vitro plasma
protein binding, and good oral bioavailability (%F=78 in
rats).
An anilinopyrimidine derivative, 10, has been reported
to be a potent IKK2 inhibitor with IC50=40 nM [19]. In
human vascular endothelial cells (Huvec), 10 inhibited the
TNF-α-induced expression of the adhesion molecules
ICAM-1 and VCAM-1 with IC50=300 nM. Administration
of 30 mg/kg oral dose of 10 inhibited TNF-α release by
75% upon LPS challenge in rats. Compound 10 exhibited
anti-inflammatory activity in a thioglycollate-induced peri-
tonitis model in mice. At a dose of 10 mg/kg s.c.
(subcutaneous), 10 inhibited neutrophil extravasation by
50% in this model.
SPC-839, whose structure is undisclosed, has been
reported to be a potent and selective IKK2 inhibitor
(IC50=20 nM) with a significant oral anti-inflammatory
activity in an adjuvant-induced arthritis model in rats [20].
T h ec o m p o u n dh a sb e e nl i c e n s e dt oS e r o n oa n dt h e
publications from this company disclose this compound as
AS602868 which is an anilinopyrimidine derivative [21].
Fig. 1 IKK2 inhibitors
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with IC50=100 nM [22]. The compound inhibited the
phosphorylation of the endogenous IKK complex in cell
lysates from TNF-α-induced HeLa cells with IC50=
150 nM. PS-1145, at an oral dose of 50 mg/kg, inhibited
LPS-induced TNF-α levels in mice by 60%.
Syk inhibitors
Spleen tyrosine kinase (Syk) is a cytosolic protein tyrosine
kinase that plays a crucial role in the IgE (FcεRI) and IgG
(Fcγ) receptor-mediated signaling in mast cells, basophils,
and macrophages leading to degranulation and cytokine
release that contribute to proinflammatory and allergic
responses. In addition, activation of Syk is involved in B-
cell receptor signaling as well as Fc receptor-mediated
antigen presentation. A variety of experimental evidence
points to the potential use of Syk inhibitors in the treatment
of various autoimmune disorders [23].
Figure 2 shows the structure of Syk inhibitors discussed
below. The oxindoles 11a and 11b have been reported to
inhibit Syk with IC50=20 and 145 nM, respectively [24].
The degranulation of rat basophilic cells (RBL-2H3),
induced by IgE/FcεRI, was inhibited by 11a and 11b with
IC50=110 and 100 nM, respectively.
Compound 12 and analogs have been reported to be
potent inhibitors of Syk with no additional data in cells or
animals (IC50=8 nM for 12)[ 25].
BAY 61-3606 has been reported to be an ATP-
competitive and selective inhibitor of Syk with IC50=
10 nM [26]. The degranulation of the RBL-2H3 cell line
was inhibited with IC50=46 nM. In an ovalbumin-induced
airway inflammation model in the rat, the efficacy of BAY
61-3606, at a dose of 30 mg/kg, b.i.d., in suppressing the
accumulation of eosinophils in BAL fluid was similar to
that of 0.3 mg/kg po, b.i.d., of dexamethasone. The less
than adequate pharmacokinetic profile of BAY 61-3606
(low AUC and fast elimination half-life) contributed to the
need for the high dose in rats for efficacy of this potent
inhibitor of Syk.
Compound 13 has been reported to be a potent and
selective Syk inhibitor with IC50=41 nM [27]. The
compound inhibited the degranulation of RBL-2H3 cells
(as measured by release of serotonin) with IC50=460 nM
and inhibited the IgE-induced passive cutaneous anaphy-
laxis reaction in mice with ED50=13.2 mg/kg s.c.
R112 and R406, two structurally related analogs, have
been reported to be potent, selective, and ATP-competitive
inhibitors of Syk. R112 inhibited Syk enzyme activity with
Ki=96 nM and inhibited anti-IgE-mediated histamine
release from primary human basophils with EC50=
280 nM [28]. In a phase II study in normal volunteers with
seasonal allergic rhinitis, intranasally delivered R112
significantly reduced clinical symptoms such as stuffy,
itchy, and runny nose, sneezes, cough, and headache [29].
R406 inhibited Syk with Ki=30 nM and inhibited anti-IgE-
induced degranulation and production and release of
leukotrienes, cytokines, and chemokines from cultured
human mast cells with EC50=40-160 nM [30]. In a CIA
model in rats, a 30 mg/kg oral b.i.d dose of R406, or a
water-soluble prodrug, R788, completely suppressed symp-
toms of inflammation and regressed arthritic score includ-
ing joint destruction [31]. In healthy human volunteers,
orally administered R406 was well tolerated, exhibited
desirable pharmacokinetic properties, and inhibited baso-
Fig. 2 Syk inhibitors
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a dose-dependent manner.
Lck inhibitors
The lymphocyte-specific kinase (Lck), belonging to the Src
family of tyrosine kinases, is expressed in T cells and
natural killer (NK) cells and is responsible for the activation
of and signaling through the T-cell receptor. Activation of
this cascade results in the upregulation of inflammatory
cytokines such as IL-2 and interferon (IFN)-γ,a n d
ultimately in the activation and proliferation of T lympho-
cytes to generate an immune response. Therefore, inhibition
of Lck is likely to elicit an immunosuppressive effect that
could be useful in the treatment of T-cell-mediated diseases
like rheumatoid arthritis, inflammatory bowel disease,
psoriasis, and organ graft rejection [32]. A large number
of compounds are reported to be potent inhibitors of Lck
(see reference 5 in reference [44] in this review). This
review will focus on the Lck inhibitors reported primarily
in the years 2006–2007 and these publications refer to the
earlier reports on Lck inhibitors. There are a number of
disclosures of Src or Src family inhibitors as anticancer
agents that have or are likely to have Lck inhibitory
activity. Most of these compounds are not covered in this
review.
Figure 3 summarizes the structure of Lck inhibitors
discussed here. An anilinopyrimidine, 14, has been reported
to inhibit Lck with IC50=19 nM with a selectivity of 3- to
30-fold against Btk, Lyn, Syk, and Txk and is proposed to
bind in the ATP site of Lck [33]. The pharmacokinetic
profile of 14 was determined to be modest.
A series of 2,3-diaryl-furopyrimidines have been
reported to be modestly selective Lck inhibitors [34].
Compound 15 inhibited Lck with IC50=98 nM and
inhibited anti-CD3/CD-28-induced secretion of IL-2 in T
cells isolated from human peripheral blood lymphocytes
with IC50=430 nM. The X-ray structure of a close analog
of 15 in Lck indicated that the compound binds in the ATP
site and that the C-H at the 2-position donates an H-bond to
the carbonyl of Glu317. Compound 16, which is closely
related to 15, is a modestly selective inhibitor of Lck with
IC50=22 nM. The binding mode and H-bonding pattern of
this class of furopyridines in Lck is shown to be similar to
that of the furopyrimidines [35].
Compound 17 is reported to be a modestly potent
inhibitor of Lck (IC50=210 nM) with significant selectiv-
ity against the other members of the Src family of kinases
[36]. The compound, which had modest oral bioavailabil-
ity in rats, inhibited anti-CD3 antibody-induced IL-2
production in mice with ED50=5 mg/kg po. A structurally
related compound, A-770041, is an inhibitor of Lck
(IC50=147 nM) with a significant selectivity against other
members of the Src family of kinases [37]. The anti-CD3
antibody-stimulated IL-2 production in human whole
blood was inhibited by this compound with IC50=
80 nM. A-770041 exhibited a desirable oral pharmacoki-
netic profile in rats and oral efficacy against heart
transplant rejection in a rat model at 10 mg/kg b.i.d.
dosing.
Compound 18 (racemic) is reported to be a potent
inhibitor of Src (IC50=20 nM) and Lck (IC50=8 nM) with
protective effects (reduction of infarct size) in a rat model
of middle cerebral artery occlusion (MCAO) [38]. A
molecular modeling-guided design of Src inhibitors has
led to the identification of 19 (Src IC50=28 nM and Lck
IC50=29 nM) with efficacy in tumor xenograft models in
mice upon intraperitoneal (i.p.) administration [39].
A series of benzimidazole-substituted anilinopyrimidines
have been reported to be potent inhibitors of Lck.
Compound 20 inhibited Lck with IC50=3 nM and inhibited
phorbol myristate acetate (PMA)-induced IL-2 production
in Jurkat Tcells with IC50=54nM[40]. However, the series
of compounds seemed to lack specificity against other Src
family kinases and lacked desirable pharmacokinetic
properties. The pyrimidopyrazine derivative, 21, is reported
to be a potent Lck inhibitor with IC50=2 nM [41]. The
cellular activity (IL-2 inhibition in T cells), selectivity
against other Src family of kinases, and pharmacokinetic
properties of 21 were less than optimal.
The anilinopyrimidine urea, 22, inhibited Lck with
IC50=87 nM and inhibited the hind paw swelling by 63%
upon oral administration twice a day at 25 mg/kg in an
adjuvant-induced arthritis model in rats [42].
Compound 23, a close structural analog of dasatinib
(BMS-354825), a marketed kinase inhibitor drug for the
treatment of chronic myelogenous leukemia (CML), is a
potent, selective, and ATP-competitive inhibitor of Lck and
other Src family kinases (IC50=1 nM for hLck) [43]. In an
ex vivo anti-CD3/CD-28-induced IL-2 production model in
mice, orally administered 23 reduced serum IL-2 levels in a
dose-dependent manner with ED50=5 mg/kg. Compound
23, which has a desirable pharmacokinetic profile in rats (%
F=65), was efficacious in reducing paw swelling upon oral
dosing at 3 mg/kg b.i.d. in a rat adjuvant arthritis model of
established disease.
The 2-amino-6-aryl-quinazoline derivative, 24,i sa
potent Lck inhibitor (IC50=0.5 nM) that is not selective
against other members of Src family kinases, p38, and
VEGFR2 [44]. In a human whole blood assay, 24 inhibited
the anti-CD3/CD28 antibody-induced IL-2 production with
IC50=113 nM. Compound 24 had a desirable pharmacoki-
netic profile in rats (%F=55) and was orally efficacious in
reducing serum levels of IL-2 in BALB/c mice with ED50=
22 mg/kg.
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The Janus kinases, JAK1, JAK2, JAK3, and Tyk2, are
cytoplasmic protein tyrosine kinases that play a critical role
in the cytokine receptor binding-triggered signal transduc-
tion through the STAT (signal transducers and activators of
transcription) proteins [45]. Binding of cytokines activates
the JAK kinases which phosphorylate and activate the
STAT proteins. The STAT proteins form homo- or hetero-
dimers and translocate to the nucleus where they induce
transcription of proinflammatory genes. JAK3 is expressed
at high levels in NK cells and normally in thymocytes,
platelets, mast cells, and inducible T and B cells. JAK3,
which is associated with the cytokine signaling through the
γc-chain of the IL-2 receptor, is critical for lymphocyte
survival, differentiation, and function. In humans, muta-
tions in JAK3 have been associated with severe combined
immunodeficiency (SCID) [46] and JAK3 knockout mice
are found to display defects in T, B, and NK cell
development and function [47]. Therefore, inhibition of
Fig. 3 Lck inhibitors
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inflammation, allergy, autoimmune disorders, and organ
transplant rejection [45]. A number of JAK3 inhibitors,
such as WHI-P131, WHI-P154, and PNU156804, which
are not highly selective against other members of the JAK
family of kinases, have been reported and included in a
review article [48]. This review will focus on JAK3
inhibitors reported during 2006–2007 and the references
cited here refer to the inhibitors reported earlier. A number
of JAK3 inhibitors have been disclosed in an abstract,
manuscript, or at scientific meetings without disclosing
their structure and/or pharmacology profile (for example,
R348, an inhibitor of JAK3 and Syk [49]); such inhibitors
are not covered in this review.
A selective JAK2 inhibitor could have a potential anti-
inflammatory effect through the inhibition of the Th1
pathway. However, the reported and available JAK2
inhibitors have some degree of JAK3 inhibitory activity
and therefore the observed effect could, at least partly, be
due to concomitant JAK3 inhibition. This review will not
include the JAK2 inhibitors that are reported to have JAK3
inhibitory activity.
Figure 4 shows the structure of JAK3 inhibitors
discussed below. PF-956980, a structurally close analog of
CP-690550, has been reported to be a potent and selective
inhibitor of JAK3 with IC50=4 nM (vs 1 nM for CP-
690550) [50]. In the human whole blood assay, the anti-
CD3/CD28 antibody-stimulated production of IFN-γ was
inhibited by PF-956980 with IC50=121 nM, while CP-
690550 had IC50=25 nM. The lower potency of PF-956980
in this assay was attributed to its higher protein binding. In
a DTH test in mice, PF-956980 when dosed by an i.v.
infusion inhibited the sheep red blood cell-induced paw
swelling with EC50=5 mg/kg.
CP-690550, a potent JAK3 inhibitor with in vitro
enzyme inhibitory and cellular activity as described above,
is found to inhibit JAK2 kinase significantly [51]. The
compound is found to exhibit profound immunosuppressive
activity in a variety of animal models [52, 53]. In a CIA
model in mice, a 5 mg/kg per day oral dose of CP-690550
was well tolerated and completely suppressed the clinical
score and severity of arthritis [53]. This compound is
reported to be efficacious in phase II trials in arthritis and
kidney transplantation [54, 55]. In a phase II study in
patients with rheumatoid arthritis, treatment with CP-
690550 at an oral dose of 15 mg b.i.d. for 6 weeks resulted
in 54% of the patients responding with an ACR50 score
[54]. The compound was not as well tolerated at a 30 mg b.
i.d. dose for 6 weeks.
A pyrrolopyrimidine series of inhibitors have been
reported to be inhibitors of JAK3 [56]. Compound 25, for
example, inhibited JAK3 with IC50=142 nM and IL-4-
induced TF-1 cell proliferation with IC50=140 nM. The
selectivity of this series of compounds over JAK2 was
modest at best in the enzyme as well as cell assays. A series
of pyrimidines with a similar activity and selectivity profile
has been reported [57]. Compound 26 inhibited JAK3 with
IC50=45 nM and inhibited IL-4-induced proliferation of
TF-1 cells with IC50=90 nM. A staurosporine analog, 27,
inhibited JAK3 with IC50=31 nM [58]. This series of
compounds lacked a desirable solubility profile and
additional data were not disclosed.
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Discovery of kinase inhibitors for the treatment of inflam-
mation and autoimmune disorders has been ongoing for
almost two decades now. Drugs targeting p38 kinase for the
treatment of arthritis and other autoimmune diseases have
progressed to phase III clinical trials, but have not been
found to be suitable for filing for registration. A number of
drugs targeting the kinases p38, JNK, MEK, IKK2, JAK3,
Lck, and Syk are currently undergoing clinical trials for the
treatment of diseases related to inflammation and autoim-
munity. It is anticipated that some of these or newer ones
will be found suitable for the treatment of rheumatoid
arthritis, psoriasis, organ transplantation, or other immune
disorders.
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